^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    TNFα inhibitor

    Related drugs:
    1m
    Infliximab as ultima ratio in a case of refractory non-Crohn's disease complex fistula system: case report and mini-review of the literature. (PubMed, Front Gastroenterol (Lausanne))
    Despite a history of recurrent urinary tract infections (UTIs) associated with mono-J catheters, the frequency of UTIs did not increase during therapy with IFX. This case indicates that infliximab may represent an effective therapeutic option for non-CD-related fistulas when there are no other therapeutic options available.
    Journal
    |
    TNFA (Tumor Necrosis Factor-Alpha)
    1m
    The pro-inflammatory cytokines IFN-α and TNF-α inhibit organoid-derived extravillous trophoblast invasion. (PubMed, iScience)
    Transcriptome profiling identified changes in several invasion-related pathways after cytokine exposure. These findings suggest that elevated IFN-α and TNF-α can directly impair trophoblast invasive capacity, potentially contributing to suboptimal placental development in inflammatory disorders.
    Journal
    |
    TNFA (Tumor Necrosis Factor-Alpha) • IFNA1 (Interferon Alpha 1)
    1m
    CAC-PPCL-001: A Study of VRD-based Regimen Combined With CART-ASCT-CART2 Treatment in Patients With Primary Plasma Cell Leukemia (clinicaltrials.gov)
    P2, N=20, Active, not recruiting, Institute of Hematology & Blood Diseases Hospital, China | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    lenalidomide • bortezomib • dexamethasone
    1m
    PRISMS: An Exploratory Study of the Potential for Rational Immune System Manipulation to Prevent Emergence of Synucleinopathy Manifestations in Persons With REM Sleep Behavior Disorder (RBD) (clinicaltrials.gov)
    P2, N=108, Not yet recruiting, Yale University | Trial completion date: Jun 2030 --> Aug 2029 | Trial primary completion date: Jan 2029 --> Aug 2029
    Trial completion date • Trial primary completion date
    1m
    Effect of adalimumab on anxiety-depression-like behaviors and learning in rats receiving cisplatin. (PubMed, Open Med (Wars))
    ADA treatment significantly reversed behavioral deficits and normalized inflammatory, cholinergic, and stress-related markers. Adalimumab attenuates cisplatin-induced cognitive and mood disturbances, likely through modulation of TNF-α-mediated neuroinflammation, cholinergic imbalance, and stress-related signaling pathways.
    Preclinical • Journal
    |
    TP53 (Tumor protein P53) • TNFA (Tumor Necrosis Factor-Alpha)
    |
    cisplatin
    1m
    Lenalidomide boosts CD1d-Vδ2 bispecific antibody-engaged Vγ9Vδ2-T cell effector functions via CD28, Notch signaling and IL-2 release. (PubMed, J Immunother Cancer)
    Our findings provide a rationale to explore the combination of CD1d-Vδ2 bsTCE and the IMiD lenalidomide in patients with CD1d-expressing hematological malignancies.
    Journal
    |
    IL2 (Interleukin 2)
    |
    lenalidomide
    2ms
    Frailty-stratified, randomised controlled Bayesian adaptive trial of bortezomib versus lenalidomide in transplant-ineligible myeloma (TI-NDMM) – the FRAIL-M study (ACTRN12619001199101)
    P1/2, N=300, Active, not recruiting, Australasian Leukaemia & Lymphoma Group | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    lenalidomide • bortezomib
    2ms
    Long-term safety and efficacy of upadacitinib compared with adalimumab in patients with rheumatoid arthritis: 7-year data from the SELECT-COMPARE study. (PubMed, RMD Open)
    The safety profile of upadacitinib remained consistent with previous analyses, with no new safety concerns through 7 years. Upadacitinib and adalimumab (continuous or rescue treatment) maintained disease activity targets throughout the 7-year treatment period. Upadacitinib exhibited an acceptable benefit-risk profile for long-term RA treatment.
    Clinical • Journal
    |
    CRP (C-reactive protein)
    |
    methotrexate
    2ms
    PRISMS: An Exploratory Study of the Potential for Rational Immune System Manipulation to Prevent Emergence of Synucleinopathy Manifestations in Persons With REM Sleep Behavior Disorder (RBD) (clinicaltrials.gov)
    P2, N=108, Not yet recruiting, Yale University | Trial completion date: Aug 2029 --> Jun 2030 | Trial primary completion date: Aug 2029 --> Jan 2029
    Trial completion date • Trial primary completion date
    2ms
    Checkpoint Inhibitor Associated Diabetes Mellitus: Early Recognition and Treatment (CERT) Project: A Pilot Study (clinicaltrials.gov)
    P=N/A, N=14, Not yet recruiting, M.D. Anderson Cancer Center | Initiation date: Apr 2026 --> Sep 2026
    Trial initiation date • Checkpoint inhibition
    2ms
    A Study on Infections in Adults With Ulcerative Colitis/Crohn's Disease (clinicaltrials.gov)
    P=N/A, N=23900, Not yet recruiting, Takeda | Trial completion date: Dec 2025 --> Dec 2026 | Initiation date: Dec 2025 --> Jul 2026 | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial completion date • Trial initiation date • Trial primary completion date
    |
    Entyvio (vedolizumab)
    2ms
    SMART: Medical Treatment Versus Surgery in Stricturing Small Bowel Crohn's Disease (clinicaltrials.gov)
    P=N/A, N=150, Not yet recruiting, Nantes University Hospital | Trial completion date: Oct 2027 --> Apr 2031 | Trial primary completion date: Oct 2027 --> Apr 2030
    Trial completion date • Trial primary completion date • Head-to-Head